334 related articles for article (PubMed ID: 31437431)
21. Lymphangioleiomyomatosis and tuberous sclerosis.
Hancock E; Tomkins S; Sampson J; Osborne J
Respir Med; 2002 Jan; 96(1):7-13. PubMed ID: 11863212
[TBL] [Abstract][Full Text] [Related]
22. Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangioleiomyomatosis.
Maisel K; Merrilees MJ; Atochina-Vasserman EN; Lian L; Obraztsova K; Rue R; Vasserman AN; Zuo N; Angel LF; Gow AJ; Kang I; Wight TN; Eruslanov E; Swartz MA; Krymskaya VP
Am J Respir Cell Mol Biol; 2018 Dec; 59(6):723-732. PubMed ID: 30095976
[TBL] [Abstract][Full Text] [Related]
23. Clinical and molecular insights into lymphangioleiomyomatosis.
Steagall WK; Taveira-DaSilva AM; Moss J
Sarcoidosis Vasc Diffuse Lung Dis; 2005 Dec; 22 Suppl 1():S49-66. PubMed ID: 16457017
[TBL] [Abstract][Full Text] [Related]
24. Lymphangioleiomyomatosis: A review.
Hohman DW; Noghrehkar D; Ratnayake S
Eur J Intern Med; 2008 Jul; 19(5):319-24. PubMed ID: 18549932
[TBL] [Abstract][Full Text] [Related]
25. Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans.
Juvet SC; McCormack FX; Kwiatkowski DJ; Downey GP
Am J Respir Cell Mol Biol; 2007 Apr; 36(4):398-408. PubMed ID: 17099139
[TBL] [Abstract][Full Text] [Related]
26. A patient with TSC1 germline mutation whose clinical phenotype was limited to lymphangioleiomyomatosis.
Sato T; Seyama K; Kumasaka T; Fujii H; Setoguchi Y; Shirai T; Tomino Y; Hino O; Fukuchi Y
J Intern Med; 2004 Aug; 256(2):166-73. PubMed ID: 15257730
[TBL] [Abstract][Full Text] [Related]
27. Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features.
Avila NA; Dwyer AJ; Rabel A; Moss J
Radiology; 2007 Jan; 242(1):277-85. PubMed ID: 17105849
[TBL] [Abstract][Full Text] [Related]
28. Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.
Krymskaya VP
Proc Am Thorac Soc; 2008 Jan; 5(1):119-26. PubMed ID: 18094094
[TBL] [Abstract][Full Text] [Related]
29. The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models.
Steagall WK; Pacheco-Rodriguez G; Darling TN; Torre O; Harari S; Moss J
Am J Respir Cell Mol Biol; 2018 Jun; 58(6):678-683. PubMed ID: 29406787
[TBL] [Abstract][Full Text] [Related]
30. Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM.
Lesma E; Grande V; Ancona S; Carelli S; Di Giulio AM; Gorio A
PLoS One; 2008; 3(10):e3558. PubMed ID: 18958173
[TBL] [Abstract][Full Text] [Related]
31. Lymphangioleiomyomatosis: a review of the literature.
Hancock E; Osborne J
Respir Med; 2002 Jan; 96(1):1-6. PubMed ID: 11863203
[TBL] [Abstract][Full Text] [Related]
32. Detection of low-prevalence somatic TSC2 mutations in sporadic pulmonary lymphangioleiomyomatosis tissues by deep sequencing.
Fujita A; Ando K; Kobayashi E; Mitani K; Okudera K; Nakashima M; Miyatake S; Tsurusaki Y; Saitsu H; Seyama K; Miyake N; Matsumoto N
Hum Genet; 2016 Jan; 135(1):61-8. PubMed ID: 26563443
[TBL] [Abstract][Full Text] [Related]
33. The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis.
Strizheva GD; Carsillo T; Kruger WD; Sullivan EJ; Ryu JH; Henske EP
Am J Respir Crit Care Med; 2001 Jan; 163(1):253-8. PubMed ID: 11208653
[TBL] [Abstract][Full Text] [Related]
34. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
Goncharova EA; Krymskaya VP
J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
[TBL] [Abstract][Full Text] [Related]
35. Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.
Cai X; Pacheco-Rodriguez G; Haughey M; Samsel L; Xu S; Wu HP; McCoy JP; Stylianou M; Darling TN; Moss J
Chest; 2014 Jan; 145(1):108-112. PubMed ID: 24051985
[TBL] [Abstract][Full Text] [Related]
36. The neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis.
Delaney SP; Julian LM; Stanford WL
Front Cell Dev Biol; 2014; 2():69. PubMed ID: 25505789
[TBL] [Abstract][Full Text] [Related]
37. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
Yu J; Parkhitko AA; Henske EP
Proc Am Thorac Soc; 2010 Feb; 7(1):48-53. PubMed ID: 20160148
[TBL] [Abstract][Full Text] [Related]
38. Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM).
Hammes SR; Krymskaya VP
Horm Cancer; 2013 Apr; 4(2):70-7. PubMed ID: 23184699
[TBL] [Abstract][Full Text] [Related]
39. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).
Goncharova EA; Goncharov DA; Fehrenbach M; Khavin I; Ducka B; Hino O; Colby TV; Merrilees MJ; Haczku A; Albelda SM; Krymskaya VP
Sci Transl Med; 2012 Oct; 4(154):154ra134. PubMed ID: 23035046
[TBL] [Abstract][Full Text] [Related]
40. TSC1 and TSC2 mutations in patients with lymphangioleiomyomatosis and tuberous sclerosis complex.
Muzykewicz DA; Sharma A; Muse V; Numis AL; Rajagopal J; Thiele EA
J Med Genet; 2009 Jul; 46(7):465-8. PubMed ID: 19419980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
